Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.

To ensure all our e-newsletters get delivered straight to your inbox, we recommend that you add us to your 'safe senders list' - otherwise known as a 'whitelist'. This is a one-time-only task to ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...